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Abstract
Background: Despite the increasing number and variety of antiepileptic drugs, nearly 30 % of epileptic patients
who receive appropriate medical attention have persisting seizures. Anticonvulsant activity has been demonstrated
for different iridoid glycoside-rich plant extracts. This study was designed to investigate the anticonvulsant
effects of iridoid glycosides purified from Feretia apodanthera and to explore the possible mechanisms involved
in antiepileptic activity.
Methods: The anticonvulsant effects of iridoid glycosides extracts were investigated against 2.7 mg/kg bicuculline- and
70 mg/kg pentylenetetrazole-induced convulsions. The behavioural and electroencephalographic manifestations of
50 mg/kg pentylenetetrazole-induced seizures in mice as a model of generalized tonic-clonic seizures were also
evaluated. Finally, the extracts were tested on the course of kindling development, kindled-seizures and oxidative stress
markers in 30 mg/kg pentylenetetrazole-kindled mice. Their effects on brain GABA content were also determined.
Results: The iridoid glycosides (30–90 mg/kg) protected mice against bicuculline-induced motor seizures in all
pre-treated animals. Behavioural seizures- and mortality-induced by 70 mg/kg pentylenetetrazole were strongly
antagonized by the extracts (60–90 mg/kg). The number of crisis (n/20 min), the cumulative duration of crisis
(sec/20 min), and the mean duration of crisis (sec) recorded in 50 mg/kg pentylenetetrazole-treated mice were
significantly decreased in all pre-treated mice with the extracts (60–90 mg/kg). Administration of the extracts
(30–90 mg/kg) significantly increased the latency to myoclonic jerks, clonic seizures as well as generalized
tonic-clonic seizures, improved the seizure mean stage and decreased the number of myoclonic jerks in
30 mg/kg pentylenetetrazole-kindled mice. Pentylenetetrazole kindling induced significant oxidative stress and
brain GABA content alteration that was reversed by pretreatment with the extracts in a dose-dependent
manner.
Conclusions: The results indicate that pretreatment with the iridoid glycosides extracts of Feretia apodenthera
improves generalized tonic-clonic seizures-induced by chemo-convulsants, protects mice against kindling
development and oxidative stress, and improves brain GABA content in pentylenetetrazole-kindled mice.
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Background
Epilepsy is a prevalent neurological disorder that ser-
iously affects the living quality of more than 65 million
people worldwide [1, 2]. It is well acknowledged that
epileptic seizures are the result of instant abnormal
hyper-synchronous electrical activity of neuronal net-
works originating locally from discharges of brain re-
gions. Imbalance between excitation and inhibition
appears as the main cause of these abnormal electrical
activities [3–5]. Individual generalized seizure types in-
clude absence, myoclonic, tonic-clonic, atonic, tonic,
and clonic symptoms. In many studies, it is not clear
that “generalized seizure” is synonymous with general-
ized onset seizure, leading to some ambiguity in classifi-
cation by seizure type [6]. Despite the increasing
number and variety of antiepileptic drugs, nearly 30 % of
epileptic patients who have been taken in charge med-
ically have persistent seizures [7]. The pharmacological
resistance of epilepsy remains therefore too widespread.
Also, current treatments of epilepsy are not satisfactory
in terms of drug-associated deleterious effects [8]. Fur-
ther, adverse effects associated with antiepileptic drugs
and recurrent seizures limit their use. The development
of new, affordable and accessible pharmacological
agents that can overcome these limitations has become
a major goal in epilepsy research [9]. The plant king-
dom has become a target of great interest and value in
the search of new drugs and lead compounds to treat
several neurological disorders, including epilepsy for
many years [7, 10].
Feretia apodanthera Del. is a member of the Rubiaceae
family. This plant is found mainly in the savanna regions of
the West African coast. Preparations of the plant have been
used in Cameroonian’s folk medicine to manage epilepsy,
infantile convulsions, anxiety, psychoses, pain and inflam-
mation for many years, and their efficacies are widely
acclaimed among the rural communities of Northern
Cameroon [11–15]. Previous studies in our laboratory
found that intra-gastric administration of an aqueous ex-
tracts of Feretia apodenthera significantly reduced the pro-
gression of kindling-induced by pentylenetetrazol, and
attenuated the oxidative stress and cognitive impairment in
kindled-mice [10]. The aqueous extracts of Feretia apo-
denthera contained flavonoids, alkaloids, saponins, tannins,
glycosides, anthraquinones and phenols, but not lipids [10].
Many of these compounds are used widely as food additives
or in traditional medicine, prompting phytochemical inves-
tigations that have in turn uncovered a variety of flavonoids,
alkaloids and iridoid glycosides [16–18]. Recent study
showed that the treatment with cornel iridoid glycosides
isolated from Cornus officinalis Sieb. et Zucc improved
neurobehavioral deficits, decreased cerebral infarct size, re-
duced nitric oxide and inhibited nuclear factor kappa B ex-
pression in the brain of rats 24 h after focal cerebral
ischemia [19, 20]. These results indicate that cornel iridoid
glycosides may improve the microenvironment of the cen-
tral nervous system by increasing growth/trophic factors
and decreasing inflammation-related factors. Bailleul et al.
[18] showed that the iridoid glycosides-rich extracts from
Feretia apodanthera decreases the spontaneous motor
activity and exploratory behaviour in mice, increases
hexobarbital-mediated sleeping time in rats, attenuates the
intensity of amphetamine-induced stereotypies in mice, and
inhibited catalepsy induced by chlorpromazine rats. It also
protected rat and rabbit, respectively, against maximal elec-
troshock- and pentylenetetrazol-induced seizures [18].
In this manuscript, in order to understand the prelim-
inary anticonvulsant mechanisms of action during epi-
lepsy and/or epileptogenesis, we purified five iridoid
glycosides from the stem barks of Feretia apodanthera
using bio-guided fractionation, and we screened the ef-
fects of the mixture of these five iridoid glycosides on
the central nervous system using experimental rodent
models of epilepsy. The aim of this study was to assess
the efficacy of iridoid glycoside extracts of Feretia apo-
danthera against convulsions induced by two chemo-
convulsants, bicuculline and pentylenetetrazole, in mice
as a model of generalized tonic-clonic seizures [21, 22].
We also evaluated the effects of this extract on the
course of kindling development, kindling-induced oxida-
tive stress markers and brain GABA content in
pentylenetetrazol-kindled mice.
Methods
Plant material and purification of iridoid glycosides
The stem barks of Feretia apodanthera used in this study
were harvested in the Mount Tenglin area of Pitoa (North
Region of Cameroon, harvesting coordinates 9°25′17″ N
and 13°27′2″ E). The plant collection was carried out on a
private land, following the permission by the owner (Mr.
Waziri Tshaolao, resident of Loumo quarter, Pitoa), to con-
duct the study on this site. The field studies did not involve
endangered or protected species. The species was authenti-
cated by the National Herbarium of Yaoundé (Cameroon),
where a voucher was deposited (Sample Number 31225/
HNC). Briefly, 500 g stem bark powder of Feretia apo-
danthera was decocted in 100 °C with 3 L water during
20 min and the solution was left to cool down. The proced-
ure was repeated 3 times. The aqueous extract (2410 mL)
was filtered, concentrated and subjected to XDA-16 macro-
porous adsorptive resins chromatographic column (250 g,
Ф 8 cm× 50 cm), which had been depurated with 95 % al-
cohol, with a flow rate of 2.0 mL/min. 600 mL distilled
water was added to elute the iridoid glycoside extract. The
end of the elution procedure was witnessed by a negative
Molish reaction. Column was cleaned afterwards with
800 mL 50 % EtOH. Total iridoid glycoside extracts
(27.9 g) was obtained after evaporation at 60 °C using a
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rotavapor. After, the extract was dissolved in distilled water
(150 mL) and chromatographed on a silica gel column pre-
washed with 20 % EtOH (300 mL). The iridorid glycosides
of Feretia apodanthera (IGEFA; 14.9 g) were obtained by
using CHCl3-MeOH-H2O (43/37/20, vol/vol/vol) as eluant.
The purities of iridoid glycosides were determined by RP-
HPLC assay. The analyses were carried out on a HPLC sys-
tem (Shimadzu-LC 20AT) equipped with UV detector,
pressure controlled by prominence pump and operated by
spinchrom Software. The HPLC separation method was de-
veloped on an Agilent reversed-phase octyldecyl silica col-
umn (TC-C18, 4.6 mm× 150 mm, 5 μm) and for elution of
the constituents, a gradient of two solvents denoted A and
B was employed. The mobile phase consisted of solvent A
(water) and solvent B (acetonitrile) with the following gradi-
ent program: 30 % B in 0 ~ 5 min; 30 % ~ 35 % B in 5 ~
15 min; 35 %~ 60 % B in 15 ~ 20 min; 60 % B in 20 ~
30 min. The flow rate was set at 1.0 mL/min, column
temperature was kept at 30 °C and the injection volume
was 20 μL. The sample was dissolved in a mixture of aceto-
nitrile and water (30:70, v/v). Iridoid glycosides were de-
tected at a wavelength of 240 nm (Fig. 1). The structures
have been successfully elucidated by using homo- and het-
eronuclear two-dimensional nuclear magnetic resonance
(NMR) techniques such as 1H-NMR, 13C-NMR, hetero-
nuclear multiple quantum coherence (HMQC) and hetero-
nuclear multiple bond correlation (HMBC) spectra, and
mass spectrum [16–18]. The purity of IGEFA was 78.5 %,
in which feretoside (1) accounted for 29 %, gardenoside (2)
18 %, geniposidic acid (3) 14 %, apodanthoside (4) 23 % and
desacetylasperolosidic acid (5) 16 %, respectively (Fig. 2).
The IGEFA was dissolved in saline 0.9 % containing di-
methyl sulfoxyde 2 % (vehicle) at the appropriate concen-
trations as indicated in the various experiments and
administered per os (p.o.) with a volume of 10 mL/kg.
Chemicals
Bicuculline, clonazepam, diazepam, flumazenil, methyl-
β-carboline-3-carboxylate (FG7142), pentylenetetrazole,
sodium valproate, reduced glutathione, thiobarbituric
acid, n-butanol, pyridine, sodium dodecyl sulphate, 5′5-
dithiobis (2-nitrobenzoic acid) and trichloroacetic acid
were obtained from Sigma, St. Louis, MO, USA. All
other chemicals and reagents used in the brain γ-
aminobutyric acid (GABA) content estimation were ob-
tained from Sigma, St. Louis, MO, USA. Diazepam was
obtained from Roche (France).
Animals
Experiments were conducted on Swiss male mice
(20–25 g) housed in appropriate cages with food and water
ad libitum. They were kept in 12 h light/dark cycle. Each
animal was used only once and was handled according to
standard protocols for the use of laboratory animals. The
investigation conforms to the Guide for the Care and Use
of Laboratory Animal published by the US National Insti-
tutes of Health (NIH; publication No. 85-23, revised 1996)
and received approval of the Cameroon National Ethical
Committee (Yaounde, Cameroon) for animal handling and
experimental procedure (Ref N°FW-IRB00001954). All ef-
forts were made to minimize animal suffering and reduce
the number of animals used.
Pharmacological tests
Bicuculline-induced motor seizures
Mice were divided into six groups of eight mice and re-
ceived orally different doses of IGEFA (15, 30, 60 and
90 mg/kg; per os (p.o.)), diazepam (positive control;
5 mg/kg, intraperitoneal (i.p.)) or vehicle (10 mL/kg;
p.o.). One hour later, all animals were injected intraperi-
toneally with bicuculline (2.7 mg/kg; subcutaneously
(s.c.)) and placed in isolated cages. Motor seizures, in-
duced by bicuculline in mice, were visually observed by
two independent investigators, unaware of the identity
of the experimental groups. They were quantified in ex-
perimental and matched control mice using the follow-
ing parameters: (a) the time to onset of the first seizure
(either tonic or clonic); (b) the duration of the clonic
Fig. 1 Typical RP-HPLC chromatograms at 240 nm for iridoid glycosides purified from the stem barks of Feretia apodanthera. (1) feretoside; (2):
gardenoside; (3): geniposidic acid; (4): apodanthoside; (5): desacetylasperolosidic acid
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and tonic components of seizures; (c) the number of
motor seizures and (d) mortality. Clonic seizures con-
sisted of rhythmic contractions of forelimbs and/or hin-
dlimbs and/or the back muscles [23, 24]. A tonic seizure
consisted of a rigid extension of the fore and/or hind
limbs with or without loss of posture. The time of obser-
vation was 120 min [24, 25].
Pentylenetetrazole-induced seizures
Experiment 1: acute administration of pentylenetetrazole at
a dose of 70 mg/kg
Mice were divided in six groups of eight mice and re-
ceived different treatments. Group I (negative control)
was treated with vehicle (10 mL/kg p.o.). Groups II to V
(test groups) were treated with 4 doses of IGEFA (15, 30,
60 and 90 mg/kg; p.o.). Group VI treated with clonaze-
pam, 0.1 mg/kg i.p., was used as positive control. Tonic-
clonic seizures were induced in mice by i.p. injection of
70 mg/kg pentylenetetrazole. The protective effect of the
different treatments given 1 h before pentylenetetrazole
injection was recorded. Animals that did not convulse
within the 10 min of observation were qualified as
protected [9].
Involvement of the GABAA receptor complex in
pentylenetetrazole (70 mg/kg) test
We also studied the effects of a selective benzodiazepine
receptor antagonist, flumazenil (1, 2, 3, 4, 5 and 6 mg/kg)
and FG7142 (4, 6, 8, 10, 12 and 14 mg/kg), an inverse
diazepam receptor agonist of the GABAA receptor com-
plex, on the anticonvulsant activity of IGEFA in order to in-
vestigate the probable involvement of benzodiazepine
receptors [26]. In these antagonistic experiments, flumaze-
nil and FG7142 were injected 15 min prior to the IGEFA
(90 mg/kg) treatments.
Experiment 2: acute administration of pentylenetetrazole
at a dose of 50 mg/kg
Surgery
Animal surgery was done as previously described by
Riban et al. [27]. Under general anesthesia (chloral hy-
drate 4 % in NaCl 0.9 %, 10 ml/kg i.p.) six groups of six
mice were implanted stereotaxically with (i) two mono-
polar surface electrodes placed over the left and right
frontoparietal cortex for pharmacological experiments or
a bipolar electrode within the right frontal sensorimotor
cortex (AP = +1.4 mm, ML = −1.6 mm, DV = −2 mm
from Bregma) for signal analysis; (ii) a monopolar elec-
trode placed over the cerebellum (reference electrode),
and (iii) a bipolar electrode inserted into the hippocam-
pus; with bregma as the reference [28]. The electrodes
were made of stainless steel wire isolated by polyester
(diameter, 0.125 mm). They were inserted in the skull
above the cortex and the cerebellum. The bipolar elec-
trode was formed of two twisted polyester insulated
stainless steel wires. The implant assembly was affixed
to the skull with dental acrylic. After the surgical im-
plantation, mice were injected with antibiotics and
Fig. 2 Chemical structures of five iridoid glycosides purified from the stem barks of Feretia apodanthera. (1) feretoside; (2): gardenoside; (3): geniposidic
acid; (4): apodanthoside; (5): desacetylasperolosidic acid
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housed individually in cages at least 14 days for recovery
before the onset of experiments [27].
Electroencephalographic recordings
Electroencephalograms (EEGs) were recorded in awake
freely moving animals using a digital acquisition system
(Biopac System, MP-100, Inc.). The signals were ampli-
fied and filtered (high pass filter 1 Hz/low pass filter
97 Hz), then digitized at a sampling rate of 256 Hz and
recorded using AcqKnowledge® software version 3.2
(Biopac Students Lab PRO software). During the record-
ing and stimulation sessions, the mice were continuously
watched to detect changes in their posture and behav-
iour. All sessions did not exceed 3 h and were performed
between 9:00 a.m. and 5:00 p.m [27]. Digital video re-
cordings were made with a webcam (Orbit Logitech
Quickcams) located inside the Faraday cage, and the ani-
mals’ behaviour was simultaneously recorded (for de-
tailed information on surgery and procedures).
Treatments and seizures induction
All pharmacological compounds were tested between
the third and the sixth week following electrodes
implantation. To test the effects of IGEFA on
pentylenetetrazole-induced seizures, the animals were
first divided into six groups of six mice each, and received
different doses of IGEFA (15, 30, 60 and 90 mg/kg; p.o.),
clonazepam (0.1 mg/kg, i.p.) or vehicle (10 mL/kg p.o.).
They were then recorded for 60 min before the pentylene-
tetrazole injection (50 mg/kg, i.p.) and then for 120 min.
The latency of first crisis, the cumulative duration of crisis,
the mean duration of crisis and number of crisis were
quantified.
Histology
Upon completion of the experiments, all mice were
injected with a lethal dose of pentobarbital (100 mg/kg,
i.p.). Their brains were removed, frozen and cut in
20 μm sections using a cryostat. Histological analysis
was performed following Cresyl Violet staining and each
implantation site was localized with reference to the
atlas of Paxinos and Watson [29].
Experiment 3: chronic administration of
pentylenetetrazole at a dose of 30 mg/kg
Experimental design
Animals were randomly divided into eight groups of six
animals each. The first group received saline intraperito-
neally while the second–seventh groups were adminis-
tered pentylenetetrazole (30 mg/kg; i.p.) dissolved in
saline on every second day (48 ± 2 h) [30]. One hour be-
fore administration of pentylenetetrazole, the first and
second groups received vehicle (10 mL/kg), the third–
sixth groups were administered IGEFA (15, 30, 60 and
90 mg/kg; p.o., respectively) orally through an intra-
gastric feeding tube. Group seven animals were adminis-
tered sodium valproate (300 mg/kg) intraperitoneally.
Pentylenetetrazole and IGEFA were administered up to
day 43 or until seizure stage 5 on two consecutive trials
was achieved, whichever was earlier. Mice were observed
for 30 min after the subconvulsant PTZ and seizure ac-
tivity scored using a scoring system from 0 to 5. In
group eighth and ninth, IGEFA (90 mg/kg) or sodium
valproate, respectively, were administered alone to study
any per se effects of the IGEFA or sodium valproate on
behaviour and biochemical parameters. Group ten ani-
mals were administered vehicle and one hour later they
received saline. Behavioural test were performed 24 h
after the last administration of pentylenetetrazole. Fol-
lowing the behavioural evaluation, the animals were
sacrificed and the whole brain was dissected for estima-
tion of markers of oxidative stress.
Kindling induction
For pentylenetetrazole kindling, a sub-convulsant dose of
pentylenetetrazole (30 mg/kg, in a volume of 10 mL/kg)
was injected intraperitoneally on every second day (i.e. day
1, day 3, day 5. . .). The first incidence of seizure with stage
five was observed between day 35 (i.e. 18th injection) and
day 39 (i.e. 20th injection). Pentylenetetrazole was adminis-
tered up to day 43 (22nd injection) or until seizure stage 5
on two consecutive trials was achieved, whichever was earl-
ier. Seizure activity was evaluated for 30 min using the
following scale [31]: Stage 0: no response; Stage 1: hyper-
activity, vibrissae twitching; Stage 2: head nodding, head
clonus and myoclonic jerk; Stage 3: unilateral forelimb clo-
nus; Stage 4: rearing with bilateral forelimb clonus; Stage 5:
generalized clonic-tonic seizures (or death within 30 min)
with loss of writing reflex. The number of myoclonic jerks
and the latencies to myoclonic jerks and generalized clonic-
tonic seizures were recorded. Animals were considered kin-
dled if they exhibited stage 5 of seizures on two consecutive
trials. Animals were also observed for 24 h mortality.
Tissue preparation
Following the behavioural testing, the mice were decapi-
tated under ether anaesthesia and the brains were
quickly removed, cleaned with ice-cold saline and stored
at −80 °C.
The whole brain of each mouse was dissected out
and divided into two cerebral hemispheres for bio-
chemical estimations. From one half, 10 % (w/v) hom-
ogenate was prepared with ice-cold 0.1 M phosphate
buffer (pH 7.4), and lipid peroxidation product,
reduced glutathione and GABA concentration were
assessed.
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Brain lipid peroxidation
Malondialdehyde, a measure of lipid peroxidation, was
measured as described by Jainkang et al. [32]. The re-
agents acetic acid 1.5 mL (20 %) pH 3.5, 1.5 mL thiobar-
bituric acid (0.8 %) and 0.2 mL sodium dodecyl sulphate
(8.1 %) were added to 0.1 mL of processed tissue sam-
ples, and then heated at 100 °C for 60 min. The mixture
was cooled with tap water and 5 mL of n-butanol/pyri-
dine (15:1), 1 mL of distilled water was added. The mix-
ture was vortexed vigorously. After centrifugation at
4000 rpm for 10 min, the organic layer was separated
and absorbance was measured at 532 nm using a spec-
trophotometer. The concentration of malondialdehyde is
expressed as nmol/g tissue.
Brain reduced glutathione
Brain reduced glutathione was measured according to
the method of Ellman [33]. The homogenate was mixed
with equal quantity of 10 % trichloroacetic acid (v/v)
and centrifuged to separate the proteins. To 0.01 mL of
this supernatant, 2 mL of phosphate buffer (pH 8.4),
0.5 mL of 5′5-dithiobis (2-nitrobenzoic acid) and 0.4 mL
of double distilled water were added. The mixture was
vortexed and the absorbance read at 412 nm within
15 min. The concentration of reduced glutathione was
expressed as μg/g tissue.
Brain GABA level
The brain GABA level was estimated in groups of mice.
The measurement of GABA, based on the method of
Lowe et al. [34], was carried out as follows. The brains
were rapidly removed, blotted, weighed and taken in ice
cold 5 mL trichloroacetic acid (10 % w/v), homogenized
and centrifuged at 10,000 g for 10 min at 0 °C. A sample
(0.1 mL) of tissue extract was taken in 0.2 mL of 0.14 M
ninhydrin solution in 0.5 M carbonate-bicarbonate buf-
fer (pH 9.9). This solution was kept in a water bath at
60 °C for 30 min then cooled and treated with 5 mL of
copper tartrate reagent (0.16 % disodium carbonate and
0.03 % copper sulphate and 0.0329 % tartaric acid). After
10 min, the fluorescence reading was taken at 377/
451 nm in a spectrofluorimeter. For GABA standards,
different amounts (20, 40, 60, 80, 100 μg) mixed with
1.5 μM glutamic acid were dissolved in 0.1 mL 10 %
trichloroacetic acid (w/v). GABA level was determined
by the measurement of the formed fluorescent product
resulting from the reaction of GABA with ninhydrin in
an alkaline medium, in the presence of glutamate [35].
The GABA content in brain was expressed in μg/g of
wet brain tissue.
Acute toxicity test
The acute toxicity test for the IGEFA was carried out to
evaluate any possible sign of toxicity. Mice of either sex
were divided into control and test groups. The first
group served as a normal control treated with vehicle.
The IGEFA (5, 15, 30, 90, 180, 360, 720, 1440, 2880 and
5760 mg/kg) was administered orally to different groups
of mice. After administration of these extracts, mice
were allowed access to food and water ad libitum and
behavioural parameters including convulsion, hyper-
activity, sedation, grooming, loss of righting reflex, in-
creased or decreased respiration, food and water intake
and mortality were observed for a period of 14 days [36].
The dose of extract necessary to induce mortality by
50 % relative to the control value, called the median le-
thal dose (LD50) was estimated according to the method
described by Litchfield and Wilcoxon [37].
Data analysis
Data were expressed as mean ± standard error of the
mean (S.E.M.) per group. The percentages of protection
against chemical-induced seizures were measured and
Fisher’s exact test (two-tailed) was used to compare per-
centages of protection. For the behavioural seizure in
the bicuculline test, the control groups were compared
to the extract-treated groups by the two-way repeated
measures analysis of variance, followed by Newman-
Keuls post hoc test. The effects of antiepileptic drugs
were assessed by counting the number of hippocampal
paroxysmal discharges in 20 min period post-injections.
Data were expressed as mean ± standard error mean of
percentage of cumulative duration, mean duration and
number of crisis per 20 min periods, compared with ve-
hicle condition. For each extract, the number of re-
corded seizures during the 20 min period post-injection
was compared between doses using a two-way analysis
of variance with repeated measures. Post-hoc compari-
sons versus vehicle conditions were performed using the
Newman-Keuls test. The differences were considered
significant at p < 0.05. In the acute toxicity test the me-
dian lethal dose (LD50) was estimated according to the
method described by Litchfield and Wilcoxon [37].
Results
Effects of IGEFA on bicuculline-induced motor seizures in
mice
In all mice, i.p. injection of bicuculline successfully induced
motor seizures as assessed by the experimenter (Table 1).
Several behavioural effects were observed after the adminis-
tration of bicuculline at a dose of 2.7 mg/kg, including
clonic and tonic components of seizures, ataxia and head
weaving. The IGEFA antagonized bicuculline-induced
motor seizures in all pretreated mice. Pretreatment with
IGEFA in doses ranging from 15–90 mg/kg signifi-
cantly influence the time to onset of the first seizure
(either clonic [F(7, 52) = 114.62; P < 0.001] or tonic
[F(7, 38) = 125.17; P < 0.001]), the duration of the
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clonic [F(7, 64) = 146.46; P < 0.001] and tonic [F(7, 29) =
132.74; P < 0.001] components of seizures, the number of
motor seizures [F(7, 42) = 106.22; P < 0.001] and the inci-
dence of death [F(7, 26) = 97.21; P < 0.001]. The durations
of both tonic and clonic seizures were significantly reduced.
A significant delay was found in the time to onset of clonic
seizures. Diazepam (5 mg/kg), an anticonvulsant, protected
the mice against bicuculline-induced motor seizures. Re-
sponses to bicuculline in mice treated with IGEFA were not
different from those of diazepam-treated mice (Table 1).
Pentylenetetrazole-induced seizures
Effects of IGEFA on acute administration of
pentylenetetrazole at a dose of 70 mg/kg
Pentylenetetrazole (70 mg/kg) produced hind-limb tonic
seizures in all the eight mice treated with vehicle. The
IGEFA increased the latency to the first seizures from 3.3 ±
1.3 min to 7.4 ± 0.6 min [F(5, 28) = 92.5; P < 0.01] at the
dose of 30 mg/kg, and from 3.3 ± 1.3 min to 9.9 ± 0.6 min
[F(5, 28) = 92.5; P < 0.001] at the dose of 60 mg/kg (Fi. 3).
The number of seizures was reduced in all the test groups
as compared to negative control. The IGEFA dose-
dependently protected animals against clonic seizures in-
duced by pentylenetetrazole. At the dose of 15 mg/kg, the
IGEFA protected 50 % (P < 0.05) of mice against seizures.
The dose of 90 mg/kg provided a 100 % (P < 0.001) protec-
tion of mice. The percentage of mortality protection was
highly significant for all tested groups when compared to
negative control. Complete protection against mortality
was achieved with 60 and 90 mg/kg IGEFA and clonaze-
pam. These effects were comparable to that of clonazepam
(0.1 mg/kg), a standard antiepileptic drug (Fig. 3).
Involvement of the GABAA receptor complex in
pentylenetetrazole induced seizures
The IGEFA, when administered alone at a dose of
90 mg/kg, protected all mice against pentylentetrazole-
induced seizures. The anticonvulsant effects of the
IGEFA were strongly antagonized by flumazenil (a spe-
cific diazepam receptor antagonist at the doses of 1, 2, 3,
4 5 and 6 mg/kg). This effect was statistically different
from the data of vehicle [F(5, 34) = 72.4; P < 0.001] but
did not exhibit differences with IGEFA administered at a
dose of 15 mg/kg. In a similar manner, the anticonvul-
sant effect of the IGEFA (90 mg/kg) was strongly antag-
onized and abolished by FG7142 (a specific inverse
diazepam receptor agonist at the doses of 4, 6, 8, 10, 12
and 14 mg/kg) (Fig. 4).
Effects of IGEFA on acute administration of
pentylenetetrazole at a dose of 50 mg/kg
Twenty min after pentylentetrazole (50 mg/kg) injection
in animals, high voltage sharp waves (1500–4500 μV, 3–
5 Hz) followed by higher frequency and low voltage
rhythmic activity (10–14 Hz, 700–1100 μV) were re-
corded. These hippocampal and cortical paroxysmal dis-
charges lasted between 20 and 60 s and their rate of
occurrence was variable between vehicle-treated group
or tested groups, with a maximum of one discharge
every other minute (Fig. 5). Behavioural seizures with
head nodding could be observed concomitantly with
hippocampal and cortical paroxysmal discharges. How-
ever, some animals also displayed stereotyped behaviour,
such as exploration or grooming. The antiepileptic ef-
fects of IGEFA were tested in pentylentetrazole-treated
mice at the doses of 15, 30, 60 and 90 mg/kg. After pen-
tylentetrazole administration at a dose of 50 mg/kg,
vehicle-treated mice presented a high-voltage fast epilep-
tiform activity with isolated spike-and-wave discharges
(no significant difference by ANOVA). In vehicle-treated
mice the number of crisis (n/20 min), the cumulative
duration of crisis (sec/20 min), and the mean duration
of crisis (sec) recorded were not significantly affected
(Fig. 5). EEG activity was strongly impaired and animals
Table 1 Effects of IGEFA or diazepam on bicuculline-induced motor seizures in mice
Treatments Dose (mg/kg) Behavioural seizures Mortality
Onset (min) Duration (min) Number of
motor seizures
Tonus Clonus Tonus Clonus
Vehicle + Saline – + – – – – – – –
Vehicle + Bic – + 2.7 2.35 ± 0.21 6.15 ± 1.12 5.32 ± 1.47 69.32 ± 1.38 24.16 ± 1.14 8/8
IGEFA + Bic 15 + 2.7 4.12 ± 0.27 11.16 ± 1.13 4.21 ± 1.15 19.12 ± 1.54* 14.57 ± 1.26 1/8***
IGEFA + Bic 30 + 2.7 6.15 ± 1.26* 13.53 ± 1.04* 3.49 ± 1.26 16.35 ± 1.29* 12.32 ± 1.39* 1/8***
IGEFA + Bic 60 + 2.7 7.21 ± 1.23* 16.17 ± 1.18* 3.15 ± 1.13 12.49 ± 1.17* 11.49 ± 1.81* 0/8***
IGEFA + Bic 90 + 2.7 7.49 ± 1.49* 18.32 ± 1.36* 2.34 ± 1.52* 11.26 ± 1.27** 11.52 ± 1.16* 0/8***
Diazepam + Bic 5 + 2.7 8.27 ± 1.28** 21.42 ± 2.19** 1.26 ± 1.24* 11.32 ± 1.45** 10.26 ± 1.28* 0/8***
Results are expressed as mean ± S.E.M., for 8 animals, bicuculline (2.7 mg/kg; s.c.) was injected intraperitonealy in mice
Bic bicuculline, IGEFA iridoid glycosides extracts of Feretia apodenthera
*P < 0.05, **P < 0.01, ***P < 0.001 significantly different compared to the vehicle, data were analysed by two-way ANOVA, followed by Newman-Keuls post hoc test
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showed signs of motor incapacitation. The acute ad-
ministration of IGEFA at the dose of 90 significantly
suppressed hippocampal and cortical paroxysmal dis-
charges in a dose-dependent way (Figs. 5 and 6) and
the number of crisis [F(5, 49) = 74.2; p < 0.001], the cumula-
tive duration of crisis [F(5, 52) = 85.5; p < 0.001], and the
mean duration of crisis [F(5, 34) = 92.5; p < 0.001] recorded
were significantly decreased or partially blocked. No mor-
tality of mice was recorded after administration of the
IGEFA at the doses of 60 and 90 mg/kg (Figs. 5 and 6).
Effects of IGEFA on chronic administration of
pentylenetetrazole at a dose of 30 mg/kg
Effects on the development of pentylenetetrazole kindling
The data shown in Table 2 represent the effects of
IGEFA or sodium valproate on treatment with a sub-
convulsant dose (30 mg/kg) of pentylenetetrazole every
2 days. The data indicate that the development of kin-
dled convulsions was directly proportional and cumula-
tive with repeated exposure to pentylenetetrazole.
Confirming previous studies (Taïwe et al., [36]), repeated
administration of a sub-convulsant dose of pentylenete-
trazole (30 mg/kg) on alternate days (for 30.00 ±
1.65 days, 15 injections) resulted in increasing convulsive
activity leading to generalized clonic-tonic seizures
(stage 5) [F(7, 28) = 124.8, P < 0.001] on two consecutive
trials. Pretreatment with IGEFA at the doses of 15 mg/kg
or vehicle did not modify the course of kindling induced by
pentylenetetrazole. However, the higher doses of IGEFA
(30, 60 and 90 mg/kg) suppressed the kindled seizure sig-
nificantly (P < 0.001), as none of the animal could achieve
stage 5 with 22 injections of pentylenetetrazole. The
statistical analysis showed a significant difference in the
development of kindling amongst the treated groups
[F(7, 28) = 68.42, p < 0.001]. Sodium valproate (300 mg/kg)
significantly (p < 0.05) delayed the course of development
of kindling by pentylenetetrazole and provided complete
protection against seizures (Table 2).
Effects of IGEFA on seizures in pentylenetetrazole kindled
mice
As shown in Table 2, IGFA administered orally at a dose of
60–90 mg/kg suppressed significantly the expression of
pentylenetetrazole-kindled seizures. Pretreatment with
IGEFA caused dose-dependent increase in the latency of
myoclonic jerks [F(7, 42) = 135.3, p < 0.001] as well as the
latency to generalized tonic-clonic seizure [F(7, 38) = 54.1,
p < 0.001] and a decrease in number of myoclonic jerks
[F(7, 32) = 104.8, p < 0.001] as compared to the vehicle-
treated pentylenetetrazole mice. IGEFA treatment produced
a significant increase in the latency to myoclonic jerks from
45.4 ± 8.6 s in the vehicle-treated pentylenetetrazole mice
to 126.5 ± 8.2 s (P < 0.001) and 173.6 ± 9.3 s (P < 0.001) in
the groups administered IGEFA at the doses of 60 and
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Fig. 3 Effects of iridoids glycosids extract from the stem barks Feretia apodanthera on acute 70 mg/kg pentylenetetrazole-induced seizures in
mice. Panel (a) latency to the first seizures, panel (b) number of seizure, panel (c) occurence of seizures (%), panel (d) mortality (%). N = 8 animals
per dose. Data were analysis by Fisher Exact Test (two-tailed) for comparison of percentages or two-way repeated measures analysis of variance,
followed by Newman-Keuls post hoc test for means comparison, *P < 0.05, **P < 0.01, ***P < 0.001, significantly different compared to the vehicle;
Clonaz, clonazepam 0.1 mg/kg. IGEFA, iridoids glycosids extract of Feretia apodanthera
Taiwe et al. BMC Complementary and Alternative Medicine  (2016) 16:285 Page 8 of 17
90 mg/kg, respectively. The results of protection offered by
IGEFA 90 mg/kg were comparable to those of sodium
valproate-treated group (Table 2). A significant difference
in the number of myoclonic jerks was observed [F(7, 42) =
128.7, p < 0.001]. This decreased from 64.3 ± 2.5 in the ve-
hicle-treated pentylenetetrazole mice to 18.5 ± 2.1 (P <
0.001), 14.2 ± 2.3 (P < 0.001) and 8.4 ± 1.2 (P < 0.001) in the
groups administered IGEFA 30, 60 and 90 mg/kg, respect-
ively (Table 2). Oral administration of IGEFA caused a sig-
nificant difference in the onset of clonic seizures [F(7, 24) =
102.2, P < 0.001]. IGEFA significantly increased the onset of
clonic seizures from 61.8 ± 8.6 s in the vehicle-treated pen-
tylenetetrazole mice to 185.2 ± 9.2 s (p < 0.05), 285.2 ± 7.6 s
(p < 0.01) and 371.5 ± 6.8 s (p < 0.001) in IGEFA 30, 60 and
90 mg/kg treated groups, respectively (Table 2).
IGEFA significantly increased the latency of general-
ized clonic-tonic seizure from 185.4 ± 15.6 s in
vehicle-treated pentylenetetrazole mice to 324.2 ±
27.1 s (P < 0.05), 388.2 ± 35.3 s (P < 0.01), and 495.5 ±
57.4 s (p < 0.01) in the groups administered IGEFA 30,
60 and 90 mg/kg, respectively (Table 2). There was a
significant difference in the duration of generalized
tonic-clonic seizure amongst the different groups [F(7,
58) = 124.1, p < 0.001]. IGEFA decreased the duration
of generalized tonic-clonic seizure from 19.5 ± 1.3 s in
the vehicle-treated pentylenetetrazole mice to 8.2 ± 0.2 s
(p < 0.05), 4.9 ± 0.2 s (p < 0.01) and 3.3 ± 0.2 s (p < 0.001) in
the groups administered 30, 60 and 90 mg/kg of the
IGEFA, respectively (Table 2). Seizure stage amongst the
groups was also significantly different [F(7, 43) =
195.3, p < 0.001]. The IGEFA significantly decreased
the seizure mean stage from 4.0 ± 0.0 in the vehicle-
treated pentylenetetrazole mice to 2.2 ± 0.3 (p < 0.05),
1.8 ± 0.3 (p < 0.01) and 1.3 ± 0.4 (p < 0.01), respectively
in the groups administered IGEFA 30, 60 and 90 mg/kg,
respectively (Table 2).
Effects of IGEFA on brain MDA levels in
pentylenetetrazole-kindled mice
The malondialdehyde level in the vehicle-treated penty-
lenetetrazole mice was significantly higher than that seen
in vehicle-treated saline mice. Pentylenetetrazole kind-
ling significantly increased (p < 0.001) the brain malon-
dialdehyde level from 142.8 ± 16.2 nmol/g wet tissue in
the vehicle + saline-treated mice to 454.6 ± 18.4 nmol/g
wet tissue in the distilled water-treated pentylenetetra-
zole mice. The IGEFA dose-dependently and signifi-
cantly attenuated the increased brain malondialdehyde
levels due to pentylenetetrazole kindling in a dose-
dependent manner [F(7, 53) = 38.2, P < 0.001]. The MDA
levels significantly decreased from 454.6 ± 18.4 nmol/g
wet tissue in the vehicle-treated pentylenetetrazole
mice to 195.1 ± 19.2 nmol/g (p < 0.05), 178.5 ±
17.4 nmol/g (p < 0.001) and 156.2 ± 16.4 nmol/g (p < 0.001)
wet tissue in groups administered IGEFA 30, 60 and
90 mg/kg, respectively. IGEFA per se (90 mg/kg) caused a
decrease in the oxidative stress as indicated by the signifi-
cant decrease (p < 0.001) in whole brain malondialdehyde
levels as compared with the vehicle-treated pentylenetetra-
zole mice (Table 3).
Effects of IGEFA on brain glutathione levels in
pentylenetetrazole-kindled mice
The marker for oxidative stress, glutathione, plays an
important role in protecting cells against oxidative dam-
age by scavenging free radicals. Thus, in the present
study, whole brain glutathione levels were measured in
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Fig. 4 Effects of the coadministration of iridoids glycosids extract
from the stem barks Feretia apodanthera (90 mg/kg) with flumazenil
(1, 2, 3, 4, 5 and 6 mg/kg; Panel a) and FG7142 (4, 6, 8, 10, 12 and
14 mg/kg; Panel b), an inverse diazepam receptor agonist of the
GABAA receptor complex, on the convulsions induced in mice by
acute 70 mg/kg pentylenetetrazole. N = 8 animals per dose. Data
were analysis by Fisher Exact Test (two-tailed), *P < 0.05, **P < 0.01,
***P < 0.001, significantly different compared to the vehicle; IGEFA,
iridoids glycosids extract of Feretia apodanthera
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reduced glutathione levels between the test groups and
the negative control group [F(7, 54) = 102.3, P < 0.001].
In vehicle-treated pentylenetetrazole animals the brain
glutathione level was 101.2 ± 14.3 μg/g-wet tissue. The
IGEFA (15, 30, 60 and 90 mg/kg, p.o.) administration in
all doses significantly increase this levels. The glutathi-
one levels are 185.8 ± 14.5 μg/g-wet tissue (p < 0.01) and
192.3 ± 16.2 μg/g-wet tissue (p < 0.01) for the mice pre-
treated by the doses of 60 and 90 mg/kg IGEFA, respect-
ively. IGEFA (90 mg/kg) alone also caused a significant
increase (199.2 ± 14.2 μg/g-wet tissue; p < 0.01) in the
brain glutathione levels as compared to the control
group (Table 3).
Effects of IGEFA on brain GABA content
The systemic administration of the IGEFA (15–30 mg/kg,
p.o.) did not produce any significant effect (p > 0.05) in the
level of brain GABA concentration in animals (Table 3).
However a significant increase in the level of brain GABA
concentration in animals administered with the IGEFA was
observed at the doses of 60 mg/kg (p < 0.01) and 90 mg/kg
(p < 0.01), and sodium valproate (300 mg/kg, p < 0.001) the
positive control, was observed 1 h after oral administration
(Table 3).
Acute toxicity
The general behavioral changes of the mice were observed
following oral administration of IGEFA at 5, 15, 30, 90, 180
and 360 mg/kg doses, which were graded through time.
The IGEFA at doses lower than 360 mg/kg in mice did not
produce any abnormality in fur, eye color, asthenia, an-
orexia, salivation, piloerection, or diarrhea in all the treated
mice, and there were no deaths recorded. Doses of 5–
360 mg/kg did not cause any detectable changes, whereas,
the doses of 720–5760 mg/kg seemed to be lethal and
caused deaths within 24–48 h. The physical signs and
symptoms of toxicity, which occurred in response to
IGEFA, were a decrease in motor activity and exploration.
The mice that died from a high dose (2880–5760 mg/kg) of
IGEFA showed signs of respiratory failure (decreased re-
spiratory rate and irregular breathing), gasping and
coma before death. The internal organs of both con-
trolled and treated groups did not show any unusual
signs and were found to be normal in both size and
Time (min)





































































































Iridoide glycosides extract 
































































Fig. 5 Effects of iridoids glycosids extract from the stem barks Feretia apodanthera on acute 50 mg/kg pentylenetetrazole-induced seizures in
mice. Panel (a) hippocampal and cortical paroxysmal discharges, panel (b) number of crisis (n/20 min), panel (c) cumulative duration of crisis
(sec/20 min), panel (d) mean duration of crisis (sec). N= 6 animals per dose. Data were analysis by two-way repeated measures analysis of variance,
followed by Newman-Keuls post hoc test, aP< 0.05, bP< 0.01, cP< 0.001, significantly different compared to the vehicle; Clonaz, clonazepam 0.1 mg/kg.
IGEFA, iridoids glycosids extract of Feretia apodanthera
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color. The median lethal dose (LD50) was calculated to
be 2197.7 mg/kg (Table 4).
Discussion
The present studies were undertaken in order to exam-
ine the anticonvulsant effects of IGEFA using mice
models of generalised tonic-clonic seizures induced by
chemicals. IGEFA has anticonvulsant effects on seizures
triggered by the GABAA receptor antagonists bicuculline
or pentylenetetrazole. This anticonvulsant effects is
demonstrated with both electroencephalographic record-
ings and behavioural observations.
Interestingly, the effects of IGEFA against bicuculline-
induced motor seizures are comparable with the stand-
ard anticonvulsant diazepam in the case of acute admin-
istration. IGEFA (30–90 mg/kg) administered acutely by
the oral route strongly protected mice against the con-
vulsions induced by bicuculline, a selective antagonist of
GABA at the GABAA-receptors [38]. Bicuculline, acts
directly on the postsynaptic GABAA receptor complex
to induce hyperactivity behaviour and seizures [39].
GABA is the major inhibitory neurotransmitter of the
mammalian nervous system and bicuculline, a competi-
tive GABAA receptor antagonist is a known pro-
convulsant [40, 41]. The dose-dependent increase in the
anticonvulsant effects of IGEFA in the bicuculline-
induced motor seizures test may be explained by an
action of IGEFA on the GABAA receptor itself in the
central nervous system. However, it may also act differ-
ently on other signalling contributors to counterbalance
the excessive stimulation provided GABAA antagonism.
It has been reported that pentylenetetrazole induces
seizures by inhibiting the GABA pathway in the central
nervous system [42–44]. In addition, altered excitatory,
inhibitory and/or modulatory neurotransmitter receptor
densities have been observed in the brains of
pentylenetetrazole-treated animals [45]. IGEFA strongly
protected mice against 70 mg/kg pentylenetetrazole-
induced seizures. This antagonism of pentylenetetrazole-
induced seizures suggested the existence of anticonvul-
sant activity and the interaction of the IGEFA with
GABAergic neurotransmission or its functional
neutralization [7, 46]. In addition, to determine which
neurotransmitter system is involved in the acute anti-
convulsant properties of IGEFA, a selective benzodiazep-
ine receptor antagonist, flumazenil or FG7142, an
inverse diazepam receptor agonist of the GABAA recep-
tor complex, were introduced in the 70 mg/kg
pentylenetetrazole-induced seizures test. Mice protection
by the IGEFA administration at a dose of 90 mg/kg was
indeed antagonized by flumazenil or FG7142. These re-
sults indicate that the effects of IGEFA should be mainly
mediated via the GABAergic system [26, 38, 47].
Pentylenetetrazole administration produces a characteris-
tic behavioral pattern of events: ear twitch, vibrissae twitch,
straub tail, myoclonic twitch, forelimb clonus, falling and
tonic hind limb extension [22]. These seizure behaviors cor-
relate with spiking activity and spike-wave discharges in the
cortex as measured by electroencephalography (EEG) [22].
Pre-treatment with IGEFA significantly attenuated the
50 mg/kg pentylenetetrazole-induced seizures in mice. The
pentylenetetrazole-induced epilepsy model is an effective
model for screening the efficacy of anti-epileptic drugs. The
behavioral and electroencephalographic manifestations of
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Fig. 6 Effects of iridoids glycosids extract from the stem barks
Feretia apodanthera on acute 50 mg/kg pentylenetetrazole-induced
seizures in mice, continued. Panel (a) cumulative duration of crisis
(sec/120 min), panel (b) mortality (%), panel (c) suppression of discharges
(%). N = 6 animals per dose. Data were analysis by Fisher Exact
Test (two-tailed) for comparison of percentages or two-way repeated
measures analysis of variance, followed by Newman-Keuls post hoc test
for means comparison; Clonaz, clonazepam 0.1 mg/kg. IGEFA, iridoids
glycosids extract of Feretia apodanthera
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Table 2 Effects of IGEFA or sodium valproate on pentylentetrazol-induced kindling in mice
Treatments Dose (mg/kg) Behavioural seizure
kindling
development (day)
Number Duration (s) Seizure mean
stageMyoclonic jerks Myoclonic jerks
latency




Vehicle + Saline – + – – – – – – – –
Vehicle + PTZ – + 30 30.00 ± 1.65 64.32 ± 2.45 45.45 ± 8.55 61.83 ± 8.61 185.45 ± 15.55 19.48 ± 1.32 4.00 ± 0.00
IGEFA + PTZ 15 + 30 32.21 ± 2.45 28.23 ± 2.14** 68.54 ± 5.25 75.16 ± 7.61 252.27 ± 24.14* 14.12 ± 1.25 2.33 ± 0.45*
IGEFA + PTZ 30 + 30 44.13 ± 2.28* 18.48 ± 2.13** 85.48 ± 4.47 185.21 ± 9.15*** 324.15 ± 27.12*** 8.24 ± 0.16** 2.16 ± 0.27*
IGEFA + PTZ 60 + 30 44.36 ± 2.32* 14.25 ± 2.34** 126.53 ± 8.15*** 285.20 ± 7.62*** 388.22 ± 35.26*** 4.86 ± 0.24*** 1.83 ± 0.28**
IGEFA + PTZ 90 + 30 43.72 ± 2.48* 8.45 ± 1.22*** 173.62 ± 9.34*** 371.52 ± 6.27*** 495.48 ± 57.41*** 3.29 ± 0.23*** 1.33 ± 0.44**
SVA + PTZ 300 + 30 43.58 ± 2.34** 7.24 ± 1.56*** 157.47 ± 8.52*** 245.57 ± 6.45*** 582.54 ± 48.36*** 2.27 ± 0.15*** 1.16 ± 0.27**
SVA + Saline 300 + – – – – – – – –
IGEFA + Saline 90 + – – – – – – – –
Results are expressed as mean ± S.E.M., for 6 animals. Data were analysis by two-way ANOVA, followed by Newman-Keuls post hoc test
PTZ pentylenetetrazol, SVA sodium valproate, IGEFA iridoid glycosides extracts of Feretia apodenthera



















pentylenetetrazole-induced seizures in rodents suggest that
the studied test is a model of generalized tonic-clonic sei-
zures [21]. The acute administration of IGEFA at the doses
of 30, 60 and 90 mg/kg significantly suppressed hippocam-
pal and cortical paroxysmal discharges in a dose-dependent
way; and the number of crisis, the cumulative duration of
crisis, and the mean duration of crisis recorded were signifi-
cantly decreased or partially blocked. In the current study it
was found that the time elapsed before the appearance of
myoclonic jerk and generalized tonic-clonic seizures was
Table 4 Acute toxicity of the IGEFA administered orally to different groups of mice
Treatment Dose (mg/kg) Sex D/T Mortality latency (h) Toxic symptoms
Vehicle – Male 0/5 – None
Female 0/5 – None
IGEFA 5 Male 0/5 – None
Female 0/5 – None
IGEFA 15 Male 0/5 – None
Female 0/5 – None
IGEFA 30 Male 0/5 – None
Female 0/5 – None
IGEFA 90 Male 0/5 – None
Female 0/5 – None
IGEFA 180 Male 0/5 – None
Female 0/5 – None
IGEFA 360 Male 0/5 – None
Female 0/5 – None
IGEFA 720 Male 3/5 36–48 Hypoactivity, piloerection, salivation
Female 5/5 36–48 Hypoactivity, piloerection, salivation
IGEFA 1440 Male 4/5 24–36 Hypoactivity, piloerection, salivation
Female 5/5 24–36 Hypoactivity, piloerection, salivation
IGEFA 2880 Male 5/5 24–36 Hypoactivity, piloerection, salivation
Female 5/5 36–48 Hypoactivity, piloerection, salivation
IGEFA 5760 Male 5/5 36–48 Asthenia, anorexia, salivation, asthenia
Female 5/5 36–48 Asthenia, anorexia, salivation, asthenia
D/T = Dead/Treated mice; None = No toxic symptoms during the observation period; mortality latency = time to death after the oral administration. The IGEFA was
two groups of mice. Mice in each group were carefully examined for any signs of toxic (behavioural changes and mortality) for 14 days. Control group received
vehicle (10 ml/kg, per os)
Table 3 Effects of IGEFA on lipid peroxidation product, brain reduced glutathione and brain GABA content in whole mice brain on
pentylentetrazole-induced kindling in mice






Vehicle + Saline – + – 142.79 ± 16.24 196.24 ± 12.31 398.51 ± 12.42
Vehicle + PTZ – + 30 454.62 ± 18.41 101.17 ± 14.24 297.38 ± 13.59
IGEFA + PTZ 15 + 30 362.24 ± 16.26* 132.15 ± 13.15* 398.53 ± 18.37
IGEFA + PTZ 30 + 30 195.13 ± 19.15** 158.47 ± 12.41* 397.62 ± 13.85
IGEFA + PTZ 60 + 30 178.47 ± 17.39** 185.75 ± 14.53** 435.49 ± 17.52*
IGEFA + PTZ 90 + 30 156.19 ± 16.43*** 192.25 ± 16.24** 455.13 ± 16.38**
SVA + PTZ 300 + 30 149.17 ± 19.75*** 195.62 ± 14.46** 452.36 ± 15.46**
SVA + Saline 300 + – 147.36 ± 17.15*** 197.37 ± 19.31** 462.37 ± 17.25**
IGEFA + Saline 90 + – 152.61 ± 17.35*** 199.21 ± 14.19** 471.41 ± 14.33**
Results are expressed as mean ± S.E.M., for 6 animals. Data were analysis by two-way ANOVA, followed by Newman-Keuls post hoc test
MDA malondialdehyde, GSH glutathione, GABA gamma-aminobutyric acid, SVA sodium valproate, IGEFA iridoid glycosides extracts of Feretia apodenthera
*P < 0.05, **P < 0.01, ***P < 0.001, significantly different compared to the vehicle-treated PTZ mice
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significantly increased in mice treated with various doses
of IGEFA. Our results demonstrate that inhibition of
excitatory drive in the cortex and hippocampus can
significantly delay seizures onset and suppress epilepti-
form discharges. This provides a proof of principle that this
IGEFA could be used in the future for treatment of general-
ized tonic-clonic seizures and for management of general-
ized epilepsy. The anticonvulsant effects of IGEFA against
pentylenetetrazole-induced seizures indicated their possible
effectiveness also against absence seizures as drugs that in-
hibit pentylenetetrazole-induced convulsions are generally
effective against absence seizures [48, 49]. Pentylenetetra-
zole induces convulsions by inhibiting the GABA pathway
in the central nervous system via the inhibition of GABAA
receptor-chloride channel complex [7, 49–51]. However,
the effects of a lyophilized aqueous extracts stem
barks extracts of Feretia apodanthera against
pentylenetetrazole-induced kindling, -induced kindled
seizures, or prolongation of hexobarbital sleeping time
have been reported [10, 18].
In the present study, sub-convulsive dose of pentylenete-
trazole, when given intraperitoneally, on alternate days in-
duced kindling in the vehicle-treated mice. The groups
which were administered IGEFA showed dose-dependent
protection against seizures. Kindled seizures are widely ac-
cepted as an animal model of epilepsy, wherein repeated
sub-threshold brain stimulation, electrical or chemical,
leads to behavioral signs of tonic and clonic seizures [52].
IGEFA significantly increased the latencies to myoclonic
jerks, clonic seizures and generalized tonic-clonic seizure as
well as duration of generalized tonic-clonic seizure as com-
pared to the vehicle-treated pentylenetetrazole mice. The
number of myoclonic jerks was also decreased by IGEFA in
a dose-dependent manner. IGEFA also decreased the mean
seizure stage dose-dependently as compared to the vehicle-
treated pentylenetetrazole mice. IGEFA produced max-
imum seizure protective effect in the dose of 90 mg/kg.
The seizure protection offered by IGEFA (90 mg/kg, p.o.)
was comparable to the standard antiepileptic drug sodium
valproate (300 mg/kg, p.o.). The protection offered by val-
proate acid on pentylenetetrazole-induced kindling is well
established [53]. Sodium valproate, as a standard anticon-
vulsant drug, has anticonvulsant effects on seizure induced
by pentylenetetrazole. Previous studies showed that sodium
valproate is able to increase brain GABA levels via various
mechanisms, including blocking GABA reuptake, inhibiting
the enzymes that break down GABA, and enhanced GABA
release from nerve terminals (central nervous system
synapses) [54, 55]. The protective effect of sodium valproate
on pentylenetetrazole-induced kindling is believed to be
achieved through different neural mechanisms including
inhibition of the voltage-dependent sodium channels, facili-
tation of GABAergic neurotransmission, reduced N-
methyl-D-aspartate-receptor mediated glutamate excitation,
increased serotonergic inhibition and attenuation of neuro-
genic inflammation [56–61].
Epilepsy has been described as a condition of excessive
neuronal discharge associated with or resulting from
oxidative stress [62, 63]. Free radicals are normal prod-
ucts of cellular aerobic metabolism involved in the de-
velopment of seizures [64]. However, when the
production of free radicals increases or defense mechan-
ism of the body decreases, they cause cellular dysfunc-
tion by attacking at the polyunsaturated sites of the
biological membranes causing lipid peroxidation. Lipid
peroxidation was described as a main factor in the eti-
ology of epilepsy. The increase in levels of malondialde-
hyde is a marker of lipid peroxidation [65]. In the
present study, pentylenetetrazole kindling increased the
level of malondialdehyde and decreased the glutathione
level in the mice brain. Pentylenetetrazole thus caused
an imbalance between antioxidant and oxidant defense
system which may be at least partially responsible for
seizures [66]. Oral administration of IGEFA prevented
the rise in brain malondialdehyde levels in a dose-
dependent manner. The significant decrease in brain
malondialdehyde levels with concomitant IGEFA admin-
istration as compared to pentylenetetrazole alone treated
mice indicates an attenuation of lipid peroxidation.
IGEFA administered at a dose of 90 mg/kg alone also
significantly decreased the malondialdehyde level as
compared to the vehicle-treated distilled water group
which supports its antioxidant property. This antioxi-
dant effect of IGEFA is coherent with its anticonvulsant
effects if one assumes indeed that excess oxidation is a
consequence of convulsions.
In addition, the present study demonstrated that
IGEFA has protective effects on pentylenetetrazole-
induced convulsions and also on oxidative damage asso-
ciated with pentylenetetrazole. The decrease level of
glutathione was observed in the distilled water-treated
pentylenetetrazole mice. IGEFA administration in all
doses demonstrated increase in glutathione level in kin-
dled mice brain tissue. Glutathione is an endogenous
antioxidant which gets converted to oxidized form. This
oxidized form of reduced glutathione reacts with free
radicals and prevent generation of most toxic hydroxyl
radical [66]. Increased lipid peroxidation during kindling
is independent of iron salts and excitotoxin. These re-
sults indicate that, during kindling, there is an exces-
sive oxidative stress pertaining as a consequence of
reduced glutathione levels [10, 67, 68]. These antioxi-
dant effects of the extracts of Feretia apodanthera in
pentylenetetrazole-kindled mice are supported by the
findings of a recent study [10] wherein oral supple-
mentation of a lyophilized aqueous extracts of Feretia
apodanthera decreased the malondialdehyde, and in-
creased the glutathione levels in brain mice. However,
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IGEFA treatment has restored the reduced glutathione
level in the brain tissues of pentylenetetrazole-kindled
mice.
The main action of the pentylenetetrazole-induced sei-
zures is reducing GABA levels [44, 69]. Reports suggest
that pentylenetetrazole-induced seizures presumably by
impairing GABA-mediated inhibition by an action at the
GABAA receptors [70]. GABA is one of the important
endogenous inhibitory neurotransmitters widely distrib-
uted in the central nervous system. Its reduction in the
brain is associated with a number of neurological disor-
ders (such as anxiety, depression and epilepsy) [70, 71].
The present study further demonstrates that, systemic
administration of IGEFA produces significant changes in
behaviour, such as sedation, hypoactivity and motor in-
coordination in mice which is indicative of either central
nervous system depressant or muscle relaxant effects
[36]. The post-synaptic GABAA receptors are implicated
in the inhibitory mechanism. Drugs that enhance
GABAA receptor-mediated inhibition, such as benzodi-
azepines, phenobarbital, valproate and felbamate, can be
used to prevent the convulsions induced by pentylenete-
trazole [48, 72]. It was found that administration of
IGEFA and sodium valproate significantly enhanced the
brain GABA concentration which again is suggestive of
an anticonvulsant action of the extracts and the refer-
ence drug. Taken together, we suggest that the anticon-
vulsant action of IGEFA is correlated to an increase in
GABA concentrations in the brain [30, 73]. This was
also evidenced in the electroclinical study. Further stud-
ies may be warranted to elucidate which exact com-
pound is responsible for these actions although it should
be noticed that all five iridoid glycosides had very resem-
bling chemical structures. It is therefore not impossible
that they possess equivalent pharmacological properties.
We did not observe any mortality case including with
the highest doses of IGEFA (range studied 5–360 mg/
kg). Therefore, IGEFA may be considered to be relatively
safe at these doses.
Conclusions
In summary, this study illustrated that IGEFA possess
potent anticonvulsant activity and significantly reduces
the progression of kindling and attenuates the oxidative
stress in mice. These finding provides scientific rationale
for the use of Feretia apodanthera extracts for the
amelioration of generalized epilepsy observed in trad-
itional medicine in some countries of Western Africa,
particularly in Cameroon. Thus, more studies are neces-
sary to clarify the chemical structural requirements in-
volved in the antiepileptic effects of the IGEFA
components and the biophysical mechanisms underlying
their pharmacological properties directly on expressed
GABAA receptors.
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